Inorganic nanoparticles for cancer therapy: A transition from lab to clinic

Samer Bayda, Mohamad Hadla, Stefano Palazzolo, Pietro Riello, Giuseppe Corona, Giuseppe Toffoli, Flavio Rizzolio

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Background: Inorganic nanoparticles (NPs) including those derived from metals (e.g., gold, silver), semiconductors (e.g., quantum dots), carbon dots, carbon nanotubes, or oxides (e.g., iron ox-ide), have been deeply investigated recently for diagnostic and therapeutic purposes in oncology. Compared to organic nanomaterials, inorganic NPs have several advantages and unique characteristics for better imaging and drug delivery. Still, only a limited number of inorganic NPs are translated into clinical practice. Method: In this review, we discuss the progression of inorganic NPs for cancer therapy and imaging, focusing our attention on opportunities, limitations and challenges for the main constituting nanomaterials, including metallic and magnetic NPs. In particular, the pre-clinical and clinical trials from the bench toward the clinic are here investigated. Results: Over the last few decades, the development of wide range of NPs with the ability to tune size, composition and functionality, has provided an excellent resource for nanomedicine. Inorganic NPs provide a great opportunity as drug carriers, due to the easy modification of targeting molecules, the control of drug release by different stimuli, and the effective delivery to target sites, thus resulting in having an improved therapeutic efficacy and in reducing side effects. Inorganic NPs are investigated in preclinical and clinical studies for the detection, diagnosis and treatment of many diseases. The stability of inorganic NPs offers a potential advantage over the traditional delivery methods. Inorganic NPs could enhance and improve current imaging and diagnostic techniques, such as MRI or PET. Even though, they have not yet been approved for drug delivery applications, their ability to respond to external stimuli is now widely investigated in clinic. Conclusion: The successful translation of inorganic NPs to the clinic requires the development of a simple, safe, cost-effective, ecofriendly mode of synthesis, and a better understanding of the safety mechanisms, biodistribution and the pharmacokinetics of NPs. However, more attention should be given to concerns on long-term toxicity, carcinogenesis, immunogenicity, inflammation and tissue damage. Although, some inorganic NPs, which were apparently promising in the preclinical phase, were found not to be successful when translated to the clinic, several encouraging NPs are currently being developed for treatment and cancer care and for a wide variety of other diseases.

Original languageEnglish
Pages (from-to)4269-4303
Number of pages35
JournalCurrent Medicinal Chemistry
Volume25
Issue number34
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Nanoparticles
Neoplasms
Therapeutics
Nanostructures
Drug delivery
Imaging techniques
Nanostructured materials
Metal Nanoparticles
Nanomedicine
Quantum Dots
Medical nanotechnology
Semiconductors
Carbon Nanotubes
Drug Carriers
Pharmacokinetics
Oncology
Diagnostic Imaging
Silver
Gold
Pharmaceutical Preparations

Keywords

  • Cancer therapy
  • Clinical trials
  • Diagnostic
  • Inorganic nanoparticles
  • Magnetic nanoparticles
  • Metallic nanoparticles
  • Nanotechnology
  • Theranostics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Inorganic nanoparticles for cancer therapy : A transition from lab to clinic. / Bayda, Samer; Hadla, Mohamad; Palazzolo, Stefano; Riello, Pietro; Corona, Giuseppe; Toffoli, Giuseppe; Rizzolio, Flavio.

In: Current Medicinal Chemistry, Vol. 25, No. 34, 01.01.2018, p. 4269-4303.

Research output: Contribution to journalReview article

Bayda, Samer ; Hadla, Mohamad ; Palazzolo, Stefano ; Riello, Pietro ; Corona, Giuseppe ; Toffoli, Giuseppe ; Rizzolio, Flavio. / Inorganic nanoparticles for cancer therapy : A transition from lab to clinic. In: Current Medicinal Chemistry. 2018 ; Vol. 25, No. 34. pp. 4269-4303.
@article{39400e1036bb4599a201fbbe060653a1,
title = "Inorganic nanoparticles for cancer therapy: A transition from lab to clinic",
abstract = "Background: Inorganic nanoparticles (NPs) including those derived from metals (e.g., gold, silver), semiconductors (e.g., quantum dots), carbon dots, carbon nanotubes, or oxides (e.g., iron ox-ide), have been deeply investigated recently for diagnostic and therapeutic purposes in oncology. Compared to organic nanomaterials, inorganic NPs have several advantages and unique characteristics for better imaging and drug delivery. Still, only a limited number of inorganic NPs are translated into clinical practice. Method: In this review, we discuss the progression of inorganic NPs for cancer therapy and imaging, focusing our attention on opportunities, limitations and challenges for the main constituting nanomaterials, including metallic and magnetic NPs. In particular, the pre-clinical and clinical trials from the bench toward the clinic are here investigated. Results: Over the last few decades, the development of wide range of NPs with the ability to tune size, composition and functionality, has provided an excellent resource for nanomedicine. Inorganic NPs provide a great opportunity as drug carriers, due to the easy modification of targeting molecules, the control of drug release by different stimuli, and the effective delivery to target sites, thus resulting in having an improved therapeutic efficacy and in reducing side effects. Inorganic NPs are investigated in preclinical and clinical studies for the detection, diagnosis and treatment of many diseases. The stability of inorganic NPs offers a potential advantage over the traditional delivery methods. Inorganic NPs could enhance and improve current imaging and diagnostic techniques, such as MRI or PET. Even though, they have not yet been approved for drug delivery applications, their ability to respond to external stimuli is now widely investigated in clinic. Conclusion: The successful translation of inorganic NPs to the clinic requires the development of a simple, safe, cost-effective, ecofriendly mode of synthesis, and a better understanding of the safety mechanisms, biodistribution and the pharmacokinetics of NPs. However, more attention should be given to concerns on long-term toxicity, carcinogenesis, immunogenicity, inflammation and tissue damage. Although, some inorganic NPs, which were apparently promising in the preclinical phase, were found not to be successful when translated to the clinic, several encouraging NPs are currently being developed for treatment and cancer care and for a wide variety of other diseases.",
keywords = "Cancer therapy, Clinical trials, Diagnostic, Inorganic nanoparticles, Magnetic nanoparticles, Metallic nanoparticles, Nanotechnology, Theranostics",
author = "Samer Bayda and Mohamad Hadla and Stefano Palazzolo and Pietro Riello and Giuseppe Corona and Giuseppe Toffoli and Flavio Rizzolio",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/0929867325666171229141156",
language = "English",
volume = "25",
pages = "4269--4303",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "34",

}

TY - JOUR

T1 - Inorganic nanoparticles for cancer therapy

T2 - A transition from lab to clinic

AU - Bayda, Samer

AU - Hadla, Mohamad

AU - Palazzolo, Stefano

AU - Riello, Pietro

AU - Corona, Giuseppe

AU - Toffoli, Giuseppe

AU - Rizzolio, Flavio

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Inorganic nanoparticles (NPs) including those derived from metals (e.g., gold, silver), semiconductors (e.g., quantum dots), carbon dots, carbon nanotubes, or oxides (e.g., iron ox-ide), have been deeply investigated recently for diagnostic and therapeutic purposes in oncology. Compared to organic nanomaterials, inorganic NPs have several advantages and unique characteristics for better imaging and drug delivery. Still, only a limited number of inorganic NPs are translated into clinical practice. Method: In this review, we discuss the progression of inorganic NPs for cancer therapy and imaging, focusing our attention on opportunities, limitations and challenges for the main constituting nanomaterials, including metallic and magnetic NPs. In particular, the pre-clinical and clinical trials from the bench toward the clinic are here investigated. Results: Over the last few decades, the development of wide range of NPs with the ability to tune size, composition and functionality, has provided an excellent resource for nanomedicine. Inorganic NPs provide a great opportunity as drug carriers, due to the easy modification of targeting molecules, the control of drug release by different stimuli, and the effective delivery to target sites, thus resulting in having an improved therapeutic efficacy and in reducing side effects. Inorganic NPs are investigated in preclinical and clinical studies for the detection, diagnosis and treatment of many diseases. The stability of inorganic NPs offers a potential advantage over the traditional delivery methods. Inorganic NPs could enhance and improve current imaging and diagnostic techniques, such as MRI or PET. Even though, they have not yet been approved for drug delivery applications, their ability to respond to external stimuli is now widely investigated in clinic. Conclusion: The successful translation of inorganic NPs to the clinic requires the development of a simple, safe, cost-effective, ecofriendly mode of synthesis, and a better understanding of the safety mechanisms, biodistribution and the pharmacokinetics of NPs. However, more attention should be given to concerns on long-term toxicity, carcinogenesis, immunogenicity, inflammation and tissue damage. Although, some inorganic NPs, which were apparently promising in the preclinical phase, were found not to be successful when translated to the clinic, several encouraging NPs are currently being developed for treatment and cancer care and for a wide variety of other diseases.

AB - Background: Inorganic nanoparticles (NPs) including those derived from metals (e.g., gold, silver), semiconductors (e.g., quantum dots), carbon dots, carbon nanotubes, or oxides (e.g., iron ox-ide), have been deeply investigated recently for diagnostic and therapeutic purposes in oncology. Compared to organic nanomaterials, inorganic NPs have several advantages and unique characteristics for better imaging and drug delivery. Still, only a limited number of inorganic NPs are translated into clinical practice. Method: In this review, we discuss the progression of inorganic NPs for cancer therapy and imaging, focusing our attention on opportunities, limitations and challenges for the main constituting nanomaterials, including metallic and magnetic NPs. In particular, the pre-clinical and clinical trials from the bench toward the clinic are here investigated. Results: Over the last few decades, the development of wide range of NPs with the ability to tune size, composition and functionality, has provided an excellent resource for nanomedicine. Inorganic NPs provide a great opportunity as drug carriers, due to the easy modification of targeting molecules, the control of drug release by different stimuli, and the effective delivery to target sites, thus resulting in having an improved therapeutic efficacy and in reducing side effects. Inorganic NPs are investigated in preclinical and clinical studies for the detection, diagnosis and treatment of many diseases. The stability of inorganic NPs offers a potential advantage over the traditional delivery methods. Inorganic NPs could enhance and improve current imaging and diagnostic techniques, such as MRI or PET. Even though, they have not yet been approved for drug delivery applications, their ability to respond to external stimuli is now widely investigated in clinic. Conclusion: The successful translation of inorganic NPs to the clinic requires the development of a simple, safe, cost-effective, ecofriendly mode of synthesis, and a better understanding of the safety mechanisms, biodistribution and the pharmacokinetics of NPs. However, more attention should be given to concerns on long-term toxicity, carcinogenesis, immunogenicity, inflammation and tissue damage. Although, some inorganic NPs, which were apparently promising in the preclinical phase, were found not to be successful when translated to the clinic, several encouraging NPs are currently being developed for treatment and cancer care and for a wide variety of other diseases.

KW - Cancer therapy

KW - Clinical trials

KW - Diagnostic

KW - Inorganic nanoparticles

KW - Magnetic nanoparticles

KW - Metallic nanoparticles

KW - Nanotechnology

KW - Theranostics

UR - http://www.scopus.com/inward/record.url?scp=85058890537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058890537&partnerID=8YFLogxK

U2 - 10.2174/0929867325666171229141156

DO - 10.2174/0929867325666171229141156

M3 - Review article

C2 - 29284391

AN - SCOPUS:85058890537

VL - 25

SP - 4269

EP - 4303

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 34

ER -